Roman Sukhovershin

Roman Sukhovershin, MD, PhD

Assistant Research Professor of Cardiovascular Sciences, Academic Institute
Assistant Research Member, Research Institute
Scientific Director, Center for RNA Therapeutics
Houston Methodist
Weill Cornell Medical College


Dr. Roman Sukhovershin received his MD with Honors from Altai State Medical University in Barnaul, Russia, where he also completed his residency in Internal Medicine. He received his PhD in Physiology and Biochemistry from the Research Institute of Physiology in Novosibirsk, Russia. His PhD studies were focused on the regulation of nitric oxide biosynthesis and, especially, on the metabolism of endogenous nitric oxide synthase inhibitors (methylarginines) in the setting of acute renal injury. Dr. Sukhovershin then received his postdoctoral training in the Department of Cardiovascular Sciences at Houston Methodist under tutelage of Dr. John Cooke. His work helped to delineate the molecular mechanisms that underlie the harmful effects of proton pump inhibitors on vascular endothelium. Besides, in collaboration with Dr. Ennio Tasciotti (Center for Musculoskeletal Regeneration, Houston Methodist) and Dr. Barry Trachtenberg (Houston Methodist DeBakey Cardiology Associates), Dr. Sukhovershin provided proof-of-concept for using biomimetic nanoparticles leukosomes for targeted delivery of drugs into atherosclerotic plaques.

In 2016 Dr. Sukhovershin joined RNAcore, where he contributed to development, improvement and upscaling processes for RNA manufacturing. He proposed HPLC-based high-throughput screening approach that allowed optimization of proprietary chemistry for RNA synthesis so that both yield and quality of RNA is higher than that of commercial kits. Besides, many internal and external RNAcore customers already benefited from mRNA purified by HPLC-based method implemented by Dr. Sukhovershin. Currently, Dr. Sukhovershin leads RNAcore team and, together with Dr. John Cooke, is committed to develop hospital-based RNA therapeutics program which would make Houston Methodist a destination hospital for RNA therapies. Under Dr. Sukhovershin’s leadership, RNAcore team establishes cGMP-compliant manufacturing platform that would allow manufacturing clinical-grade RNA with the scale to support first-in-man trials, and flexibility to enable personalized RNA therapies.

Dr. Sukhovershin has published in high-impact journals, such as Circulation Research, Journal of American College of Cardiology, and Theranostics. He is a recipient of several scientific awards, actively involved in professional societies, including the American Heart Association, and served as a co-chair of the Houston Methodist Postdoctoral Association.

Description of Research

As a foreign-trained physician-scientist, Dr. Sukhovershin is passionate about translational and collaborative work that would bring RNA-based therapies into the clinic. He is particularly interested in the following:

  • New targets for RNA therapeutics (especially, for cardiovascular applications and regeneration)
  • RNA products optimization to enhance stability, translatability and reduce toxicity
  • Targeted tissue-specific RNA delivery
  • Novel therapies for atherosclerosis and cardiovascular disease

Areas Of Expertise

Atherosclerosis Cardiovascular disease RNA therapeutics Nitric oxide (NO) Asymmetric dimethylarginine (ADMA) Proton pump inhibitor (PPI)

Hospital-Based RNA Therapeutics
Damase, TR, Sukhovershin, R, Zhang, M, Kiss, DL & Cooke, JP 2021, . in mRNA Therapeutics: Springer.

RNA therapeutics for cardiovascular disease
Boada, C, Sukhovershin, R, Pettigrew, R & Cooke, JP 2021, , Current Opinion in Cardiology, vol. 36, no. 3, pp. 256-263.

The Limitless Future of RNA Therapeutics
Damase, TR, Sukhovershin, R, Boada, C, Taraballi, F, Pettigrew, RI & Cooke, JP 2021, , Frontiers in Bioengineering and Biotechnology, vol. 9, 628137.

mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration
Chanda, PK, Sukhovershin, R & Cooke, JP 2021, , Cells, vol. 10, no. 1, 187, pp. 1-13.

Rapamycin-Loaded Leukosomes Reverse Vascular Inflammation
Boada, C, Zinger, A, Tsao, C, Zhao, P, MARTINEZ JONATHAN, O, Hartman, KA, Naoi, T, Sukhovershin, R, Sushnitha, M, Molinaro, R, Trachtenberg, BH, Cooke, JP & Tasciotti, E 2019, , Circulation Research. <>

Novel Markers for Adverse Events in Atrial Fibrillation
Cooke, JP & Sukhovershin, RA 2018, , Journal of the American College of Cardiology, vol. 72, no. 7, pp. 734-737.

Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery
Martinez, JO, Molinaro, R, Hartman, KA, Boada, C, Sukhovershin, R, De Rosa, E, Kirui, D, Zhang, S, Evangelopoulos, M, Carter, AM, Bibb, JA, Cooke, JP & Tasciotti, E 2018, , Theranostics, vol. 8, no. 4, pp. 1131-1145.

Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression
Sukhovershin, RA, Toledano Furman, NE, Tasciotti, E & Trachtenberg, BH 2016, , Methodist DeBakey cardiovascular journal, vol. 12, no. 3, pp. 141-145.

Proton Pump Inhibitors Accelerate Endothelial Senescence
Yepuri, G, Sukhovershin, R, Nazari-Shafti, TZ, Petrascheck, M, Ghebre, YT & Cooke, JP 2016, , Circulation Research, vol. 118, no. 12, pp. e36-e42.

Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy
Sukhovershin, RA, Yepuri, G & Ghebremariam, YT 2015, , Methodist DeBakey cardiovascular journal, vol. 11, no. 3, pp. 166-71.

Methylated arginine analogues: Their potential role in atherosclerosis and cognition using the poloxamer-407-induced mouse model of dyslipidemia
Gilinsky, MA, Johnston, TP, Zhukova, NA, Dubrovina, NI, Latysheva, TV, Naumenko, SE & Sukhovershin, RA 2015, , Canadian Journal of Physiology and Pharmacology, vol. 94, no. 11, pp. 1122-1131.

Methylarginines in Mice with Experimental Atherosclerosis
Gilinsky, MA, Sukhovershin, RA & Cherkanova, MS 2015, , Bulletin of Experimental Biology and Medicine, vol. 160, no. 1, pp. 13-16.

Lansoprazole worsens asthma control in poor metabolizers: Is nitric oxide involved?
Sukhovershin, RA, Ghebremariam, YT & Cooke, JP 2015, , Annals of the American Thoracic Society, vol. 12, no. 7, pp. 1109-1110.

The influence of acute renal injury on arginine and methylarginines metabolism
Sukhovershin, RA & Gilinsky, MA 2013, , Renal Failure, vol. 35, no. 10, pp. 1404-1411.

Endogenous regulators of NO bioavailability in rats with acute renal failure
Sukhovershin, RA & Gilinsky, MA 2012, , Bulletin of Experimental Biology and Medicine, vol. 153, no. 4, pp. 444-447.

[The role of asymmetric dimethylarginine in the regulation of nitric oxide level in rats with acute renal injury].
Sukhovershin, R & Gilinskii, MA 2012, , Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, vol. 98, no. 4, pp. 497-505.

Cerebral hemodynamic reaction to physical exercise of moderate intensity
Kulikov, VP, Gatalskii, KK, Doronina, NL, Kisarova, IA & Sukhovershin, PA 2007, , Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, vol. 93, no. 2, pp. 161-168.